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Abstract
With the continuing march of the AIDS epidemic and little hope for an effective vaccine in the near
future, work to develop a topical strategy to prevent HIV infection is increasingly important. This
stated, the track record of large scale "microbicide" trials has been disappointing with nonspecific
inhibitors either failing to protect women from infection or even increasing HIV acquisition. Newer
strategies that target directly the elements needed for viral entry into cells have shown promise in
non-human primate models of HIV transmission and as these agents have not yet been broadly
introduced in regions of highest HIV prevalence, they are particularly attractive for prophylaxis. We
review here the agents that can block HIV cellular entry and that show promise as topical strategies
or "virustats" to prevent mucosal transmission of HIV infection
Introduction: the compelling need for 
prevention of HIV infection
As the pandemic spread of HIV infection and AIDS con-
tinues, there is increasing need to develop strategies for its
containment. Since sexual transmission of HIV infection
is the most important route of transmission throughout
the world [1], approaches to limit transmission by this
route are especially needed. To date, there is reason to
believe that three prevention strategies work in this arena,
but there are limits to their implementation. First it is a
tautology that avoidance of sex will result in a decrease in
sexual transmission of HIV. Despite innumerable cam-
paigns encouraging abstinence or monogamy and some
indications that some of these campaigns might have had
limited effect [2], we haven't yet figured out a way to con-
vince ourselves that avoidance of sex is better than having
it when the opportunity arises. Likewise, while there is
strong evidence that regular use of condoms will decrease
the risk of HIV transmission by at least 80% [3], there is
often resistance to their use for reasons that may relate to
perceptions of pleasure, perceptions of trust and fidelity,
social norms, and of access and opportunity [4]. Finally
while there is strong evidence that male circumcision will
decrease the risk of HIV acquisition by half or more [5-7],
broad "roll-out" of circumcision has not yet been imple-
mented. Though this is likely to be remedied soon and
should have measureable impact on HIV spread, protec-
tion is not complete and additional methods of preven-
tion will surely be needed
While a vaccine that is capable of providing sterilizing
immunity to HIV is rightly the goal of intensive research,
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vaccine candidates plausibly capable of inducing such
protection are not nearly within reach and in fact there is
only limited insight into what it will take to design such
candidates [8,9]. Thus there is compelling need to develop
additional effective strategies for the prevention of sexual
transmission of HIV.
We should no longer develop "Microbicides" for the 
prevention of HIV infection
The term "microbicide" has been used to describe agents
that can be applied topically to mucosal surfaces in order
to prevent HIV transmission. We think that the term is
both inaccurate and misleading and should not be used in
polite company (at least not when discussing HIV preven-
tion). We outline below why we would like to see this
word take its rightful place beside "impact" (the verb) and
the thoughtless "gerundification" of perfectly proper
nouns such as "text" and "parent".
First, the most promising topical strategies to prevent HIV
transmission are not microbicidal in so far as they do not
kill microbes (or viruses for that matter). They achieve
their effect by blocking HIV replication through interfer-
ence with either a viral or a host element that is necessary
for viral propagation. Second (and this is where even
words can be dangerous), those agents that were in fact
microbicidal (i.e., they destroyed viruses and other
microbes in the test tube) have been disastrous failures in
the clinic, in large part because they were broadly "micro-
bicidal". There was early hope that topical application of
a single agent might kill or otherwise render non-infec-
tious HIV as well as a variety of other sexually transmissi-
ble pathogens. Unfortunately, the agents that had this
broad killing activity were primarily soaps or detergents
that dissolved the microbial cell wall or membrane. This
activity was predictably toxic to human cells as the lipid
membrane that surrounds the HIV capsid is always
derived from the human cell in which the virions were
produced. This hazard turned out to be significant in the
clinic as topical application of the detergent N-9 not only
failed to protect against HIV acquisition, but also likely
increased infection risk as a result of toxicity to the vaginal
mucosal surface [10]. A further trial of another microbi-
cide detergent -SAVVY- nearly doubled the risk of HIV
acquisition among recipients (hazard ratio 1.7), but with
few events, these differences were not significant (CI =
0.9–3.5) [11]. Despite these predictably discouraging
results, other detergents are still being studied with the
aim of preventing HIV transmission. Such studies make us
very anxious.
We would propose, therefore, that the term "microbicide"
not be used when discussing HIV prevention. Instead, per-
haps, a complex but more accurate phrase could be "top-
ical prevention strategies," or even the simpler term
"virustats," since the most promising agents effectively
block HIV from replicating but do not "kill" it. This pro-
posal may be a losing battle as there is something to be
gained from branding a term and acknowledging its wide
recognition by both the scientific and the lay communi-
ties. Nonetheless, one of the major advantages to writing
a review article (and there are many downsides) is that
you can pick your own battles and hope that others might
see it your way.
What topical prevention strategies might be implemented 
to prevent sexual transmission of HIV?
The viral replication cycle offers a number of opportuni-
ties for intervention to prevent HIV acquisition [12-15].
We will focus this piece on strategies that block HIV entry
into cells, strategies that to us are among the most attrac-
tive for prevention. Strategies targeting later points in the
viral replication cycle also are quite plausible but with
some limitations as will be discussed below.
HIV entry into host cells
HIV cellular invasion is a complicated process coordi-
nated by the sequential binding of the viral envelope to
cellular receptors (Figure 1). The responsible viral compo-
nent, Env, is a heavily glycosylated, trimeric protein com-
posed of two subunits, gp120 and gp41. Initial cellular
capture of the virus is achieved through Env glycans that
bind cellular lectins (DC-Sign and related C-type
lectins)[16]. For some special antigen-presenting cells
(mucosal dendritic cells), captured virions can be con-
veyed to a protected cellular compartment, enabling infec-
tious HIV to be transported in situ to adjacent lymphoid
tissue containing an abundance of infectable target cells
[17]. On susceptible target cells, the Env-lectin interac-
tions keep the virus close to the membrane, facilitating the
binding of gp120 to its primary receptor, CD4[18]. This
event induces a structural change in gp120 that exposes
new surfaces capable of binding 7-transmembrane G-pro-
tein-coupled chemokine receptors (referred to as HIV
coreceptors). In humans, the key coreceptors utilized by
HIV are CCR5 and CXCR4, even though numerous other
chemokine receptors appear to support infection in vitro.
Interestingly, almost all cases of acute infection involve
CCR5-using HIV. Consequently, individuals lacking cell
surface-expressed CCR5 (owing to a 32-base pair deletion
in the open reading frame of both alleles) are almost com-
pletely protected from acquiring HIV infection [19,20]. In
the rare instances in which these individuals have been
found to be HIV positive, the viruses were shown to utilize
CXCR4 for cellular entry [21-32].
The interactions between gp120 and cellular receptors
trigger a series of conformational transitions in gp41 that
ultimately lead to the fusion of viral and cellular mem-
branes. Initially, gp41 extends to insert its N-terminalRetrovirology 2008, 5:116 http://www.retrovirology.com/content/5/1/116
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"fusion peptide" segment into the target cell membrane
[33]. Because gp41 already contains a transmembrane
region embedded in the viral envelope, this high energy,
extended conformation essentially bridges the space
between target cell and virus. Driven by the tight associa-
tion of heptad-repeat (HR) segments in its N- and C-ter-
minal regions, the gp41 ectodomain eventually collapses
into a compact structure known as a trimer-of-hair-
pins[34]. Formation of the gp41 trimer-of-hairpins brings
the fusion peptide, the transmembrane region and their
associated membranes into the close proximity required
for the fusion process. Although evidence supports the
gp120-CD4 interaction initiating gp41 structural changes,
the precise role of gp120-coreceptor interaction in pro-
moting formation of the gp41 trimer-of-hairpins remains
a mystery [35,36].
Strategies to block HIV entry into cells
Blocking the entry of HIV into target cells should be an
effective mechanism to neutralize HIV infectivity since
cellular infection and use of cellular machinery are neces-
sary for production of new viruses. Entry can be blocked
by targeting either the viral envelope glycoprotein, or host
elements such as CD4 or CCR5.
Inhibition of HIV replication by targeting the HIV envelope
Polyanions
A variety of negatively charged polyanions such as cellu-
lose sulfate, dextran sulfate, carageenan and PRO-2000
are capable of binding to the HIV envelope and prevent-
ing cellular infection. In part because these agents are
inexpensive to make and showed some in vitro activity, a
number of them were accelerated into development as
topical prevention strategies. Unfortunately, these agents
tend to be far more active against the more positively
charged CXCR4-using (X4-tropic) viruses than they are
against the CCR5-using (R5-tropic) viruses that are
responsible for most instance of HIV transmission
[37,38]. In fact both dextran sulfate and cellulose sulfate
can actually increase HIV infectivity in vitro [39,40], and
plasma levels of HIV were increased in persons receiving
treatment with dextran sulfate in vivo [41]. Thus, it is not
surprising that several large placebo-controlled trials of
these agents have failed to demonstrate protection against
HIV infection [40]. In some instances, HIV transmission
may even have been increased in persons receiving cellu-
lose sulfate. Although one arm of a polyanion (PRO-
2000) trial is still ongoing and we do not know yet
whether this approach will prove useful, the poor track
record of trials with other anions and the recent termina-
tion of the higher dose arm of this same PRO-2000 trial
for futility tempers enthusiasm for this approach. On the
other hand, the relationship between in vitro enhance-
ment of infection and in vivo protection remains unclear.
A recent study confirmed in vitro enhancement of infec-
tion by the polyanion carageenan but showed significant
protection from SHIV vaginal challenge in rhesus
macaques [42]. At the same time, this agent failed to pro-
tect women from HIV infection in a large randomized
controlled clinical trial [43]. How much of this relates to
the activity of the agent, the durability of its protection or
the consistency of its application in the clinical trial
HIV entry and its inhibition Figure 1
HIV entry and its inhibition. In the native conformation of Env, a canopy of three gp120 molecules (green) covers gp41, 
holding the trimer in a metastable conformation. Binding to cellular lectins (black) keeps Env close to the cellular membrane, 
facilitating subsequent interactions with CD4 (orange) and a chemokine receptor (CoR, purple). These gp120/receptor inter-
actions trigger gp41 to extend and insert its N-terminal fusion peptide segment (red) into the target cell membrane. Ultimately, 
the exposed heptad repeat segments in the N- and C-terminal regions of the gp41 ectodomain [labeled N (gray) and C (blue)] 
associate to form the trimer-of-hairpins structure, juxtaposing viral and cellular membranes in a manner crucial for membrane 
fusion. HIV entry inhibitors investigated as potential topical prevention strategies are listed in red below each modeled transi-
tion.Retrovirology 2008, 5:116 http://www.retrovirology.com/content/5/1/116
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remains to be determined. SPL 7013 is a polylysine based
polyanionic dendrimer with naphthalene disulfonic acid
surface groups that when formulated as a 5% gel protected
6 of 6 pigtailed macaques from infection with the pre-
dominantly CXCR4 tropic SHIV 89.6 [44]. Similar in vitro
antiviral activity was reported against both SHIV 89.6 and
the R5 tropic SHIV 163P3 [44] but to date, no in vivo chal-
lenge studies using an R5 tropic virus have been reported.
Lectins
Cyanovirin and griffithisin are small lectins that demon-
strate potent in vitro activity against HIV replication
[45,46]. They appear to bind Env glycans and interfere
with cellular entry, most likely by blocking viral capture
through cellular C-type lectins and/or interfering with
gp120 binding to cellular CD4 and coreceptor. Cyanovi-
rin is a 101 amino-acid protein produced by the cyano-
bacterium Nostoc ellipsosporum. Its gene has been inserted
into lactobacilli that are common residents among the
vaginal microbiota [47]. Sustained expression of cyanovi-
rin by these bacteria within the vagina may provide some
protection against vaginal acquisition of HIV infection,
but this observation remains to be shown in a relevant
animal model. Griffithisin is a 121 amino-acid protein
derived from the algae Griffithsia and is currently being
explored as a candidate for topical prevention of HIV
transmission [48]. Immunogenicity is a potential issue for
these foreign proteins after repeated topical application.
Moreover, there is the additional risk that these lectins
will bind to and crosslink glycoproteins present on
immune cell surfaces, potentially activating these cells
nonspecifically and stimulating mitogenic activity [49].
How much of a problem these concerns will be remains
to be determined.
Monoclonal antibodies
In many viral infections, antibodies that can neutralize
infectivity have the ability to provide sterilizing immunity
against infection. Although neutralizing antibodies are
readily demonstrable in the plasmas of persons who
acquire HIV infection, these antibodies are typically type-
specific and virus escapes rapidly from neutralizing activ-
ity [50,51]. A small number of human or "humanized"
broadly neutralizing monoclonal antibodies (mAb) have
been developed that bind to limited regions of the HIV
envelope [52]. Of these, mAb b12, which recognizes the
CD4 binding domain of HIV gp120, provided partial pro-
tection (9 of 12 animals protected) in the rhesus vaginal
challenge model [53]. Two others, mAbs 2F5 (which tar-
gets the C-terminal region of the gp41 ectodomain) and
2G12 (which recognizes sugar moieties on gp120) also
provided partial protection when co-administered sys-
temically in combination with polyclonal anti-HIV
immunoglobulin [54]. The virus utilized in these studies,
however, was SHIV 89.6, which predominantly uses
CXCR4 for entry. (It should be noted that in these latter
studies, the antibodies were not applied topically). Such
antibodies are costly to produce in large scale because they
must be generated in mammalian cells capable of post-
translational modification. Nonetheless, their activity in
vivo demonstrates that targeting these regions of the viral
envelope might provide a plausible topical protection
strategy for a product that is simpler to make. In addition,
as newer technologies are being developed to express bio-
logically active antibodies or their fragments (see for
example [55,56]), these approaches may become increas-
ingly affordable and practicable.
BMS 377806
This small molecule binds to gp120 and interferes with
cellular receptor interactions, thereby blocking infectivity
[57]. While there is still some uncertainty as to the precise
mechanism of activity of this agent, it provides substantial
protection (6 of 8 animals protected) when used alone
and, when used in combination with other entry inhibi-
tors, can provide complete protection [58].
Inhibitors of gp41
Agents that disrupt gp41 conformational changes
required for HIV membrane fusion effectively inhibit viral
entry[34]. The best characterized are linear peptides origi-
nally derived from the C-terminal heptad repeat segment
(C-HR) and adjacent membrane-proximal region of the
gp41 ectodomain [59,60]. These so-called C-peptides
bind the gp41 N-terminal heptad repeat segment (N-HR)
exposed in the extended, prehairpin intermediate confor-
mation of the ectodomain [34]. Once bound, they block
association of N-HR and C-HR segments, thereby disrupt-
ing trimer-of-hairpins formation and inhibiting viral
membrane fusion. While C-peptides are only effective
during a short kinetic window between CD4-gp120 bind-
ing and trimer-of-hairpins formation, they can possess
potent (low nanomolar) antiviral activity in vitro. With
parenteral administration of 90 to 180 mg/day, the 36-
mer C-peptide enfuvirtide (T-20) can effectively suppress
HIV replication in humans and is currently used as a sal-
vage therapy for HIV-1 infected individuals [61] Surpris-
ingly, the effectiveness of enfuvirtide as a topical
protective agent against mucosal HIV transmission has
not been reported. However, the second generation agent
T-1249 and an extended C-peptide C52L have been
shown to effectively reduce HIV mucosal transmission in
macaque studies [62,63]. As a monotherapy, T-1249 com-
pletely protected against infection following vaginal SHIV
challenge, but only at concentrations in excess of 100 μM.
For C52L, concentrations as high as 1.5 mM only afforded
protection in 60% of challenged animals. However, the
activity of C52L is enhanced in combination with other
antiviral agents (especially inhibitors of coreceptor bind-
ing), consistent with the synergistic activity between C-Retrovirology 2008, 5:116 http://www.retrovirology.com/content/5/1/116
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peptides and different HIV entry inhibitors observed in
vitro [64,65]. As with cyanovirin, mucosal bacteria secret-
ing C-peptides have been generated, but whether coloni-
zation with these microorganisms can protect against HIV
transmission remains to be tested [66].
The 5 order-of-magnitude disparity in C-peptide poten-
cies determined from in vitro infectivity experiments and
from vaginal challenge studies is disconcerting, and its
cause unknown. Similar differences are also observed for
entry inhibitors of different classes, leading many investi-
gators to speculate that these observations reflect some
intrinsic difficulty in delivering inhibitors to sites where
they need to act [67]. Two aspects of C-peptide inhibition
compound this problem. First, C-peptides target an inter-
mediate state during the entry process and, thus, must be
present at high levels at the site of viral infection[34]. They
do not bind the Env native state prior to CD4 interaction,
and they do not work on target cells. Where in the vaginal
mucosa HIV first encounters and infects target cells
remains unknown, but such events are likely to take place
in the deep epithelium or submucosa. Hence, to effec-
tively block all mucosal transmission, C-peptides must
passively diffuse a significant distance through the vaginal
epithelium and surrounding tissue. Second, C-peptides
are unstructured in solution and readily susceptible to
proteolysis [68]. The vaginal milieu and surrounding tis-
sues are full of proteases that can potentially limit the bio-
availability these antiviral agents. To date, the search for
non-peptide, small molecule gp41 inhibitors has not
yielded compounds with sufficient antiviral potency.
Recently, however, protease-insensitive peptides com-
posed of d-amino acids (D-peptides) have been devel-
oped that target a small region of the N-terminal HR
segment [69,70]. Crosslinked versions of these D-peptides
show potent, broad-spectrum inhibitory activity and rep-
resent promising candidates for a future topical antiviral
strategy.
Inhibition of HIV replication by targeting host cell surface 
receptors
Blockade of CD4
In principal, blockade of CD4 by targeting the envelope
binding domain of the HIV receptor should decrease HIV
infectivity and one humanized monoclonal antibody,
TNX-355 (Ibalizumab) has demonstrated antiretroviral
activity in HIV infected persons after systemic administra-
tion [71], however there do not appear to be plans to
develop this reagent as a topical prevention strategy.
Blockade of CCR5
Since the original discovery that CCR5 and CXCR4 are
critical to HIV entry [72-78], major effort has been
devoted to developing reagents that target these corecep-
tors and disrupt their interactions with gp120 [13,79]. To
date, efforts to develop CCR5 inhibitors have been much
more successful than strategies targeting CXCR4. From the
standpoint of a topical prevention strategy, CCR5 inhibi-
tion appears to be much more important as almost all
cases of new infection are caused by R5-tropic viruses. This
point is underscored by the rarity of HIV infected individ-
uals who lack surface-expressed CCR5. Nonetheless, there
was no certainty that mucosal blockade of CCR5 would be
sufficient to provide protection against HIV transmission.
Viruses captured by DC-SIGN (or related C-type lectins)
on certain submucosal dendritic cells might be trans-
ported and presented for trans-infection to CD4+ CCR5+
immune cells found deeper within the body. Thus it was
important to learn that topical blockade of CCR5 was suf-
ficient to provide very high level [58] or complete [80]
protection against vaginal transmission of the R5 tropic
SHIV 16P3.
There are now three strategies to block HIV replication by
targeting CCR5. Humanized monoclonal antibodies have
been developed that bind to CCR5 and block its interac-
tion with the HIV envelope. Both HGS 004 and PRO 140
have been given systemically to persons with HIV infec-
tion and have demonstrable antiretroviral activity in vivo
[81,82]. Neither is being developed for topical applica-
tion. A number of small molecule allosteric inhibitors of
CCR5 have been developed for systemic administration;
one of these, maraviroc, has been approved for treatment
of HIV infection, and another, vicriviroc, has demon-
strated in vivo efficacy [83,84]. A third small molecule
CCR5 inhibitor, CMPD 167 (Merck), is not being devel-
oped for systemic administration but has shown protec-
tive activity in the rhesus vaginal challenge model [58].
The advantages to developing these small molecule CCR5
inhibitors as topical agents to prevent HIV infection
include 1) the rigorous safety testing that they have under-
gone during trials of systemic administration, 2) the fact
that they are relatively inexpensive to produce and 3) their
lack of agonist activity on the chemokine receptor. In fact,
these molecules block the agonist activity of natural
chemokine ligands and, thus, are expected to be anti-
inflammatory. Conceivably, this property might protect
the vaginal mucosa from the inflammation caused by
concurrent bacterial vaginosis [85] or sexually transmissi-
ble infections [86] that have been linked to enhanced risk
for HIV acquisition.
A third mechanism by which CCR5 can be targeted to
block mucosal HIV transmission is by application of their
natural or modified chemokine ligands. By experimental
modification of the amino terminus of RANTES, Robin
Offord and Oliver Hartley have developed a series of
RANTES analogues with substantially greater antiretrovi-
ral activity than the native molecule [87]. The first lead
molecule to be tested in the non-human primate vaginalRetrovirology 2008, 5:116 http://www.retrovirology.com/content/5/1/116
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challenge model, PSC-RANTES, has several non-natural
amino acid residues of the amino terminus which are
responsible for its antiretroviral activity at sub-nanomolar
concentrations. PSC-RANTES is an agonist of CCR5 and
induces durable (at least 24 hrs) internalization of CCR5,
rendering the coreceptor inaccessible to the viral envelope
[87]. When tested in the rhesus vaginal challenge model,
PSC-RANTES completely protected 12 of 12 animals from
infection with SHIV 162P3 ([80] and Veazey, unpub-
lished). Because the amino terminus of PSC- RANTES
comprised non-natural amino acids, the molecule cannot
be produced completely by biosynthesis, rendering cost of
chemical synthesis an insurmountable obstacle for large
scale production. For this reason, a novel phage display
selection method was applied to develop recombinant
RANTES variants with high level potency [88]. The selec-
tion strategy successfully identified two fully recombinant
molecules, 5P12 and 6P4 RANTES, with the comparable
in vitro antiviral potency to that of PSC-RANTES [89].
Morevoer, both fully recombinant molecules completely
protected 5 of 5 challenged monkeys from SHIV 162P3
infection in the rhesus vaginal challenge model [90].
These new molecules are stable at high temperatures and
are resistant to loss of biologic activity after exposure to
vaginal and seminal fluids [91]. Because they are fully
recombinant, it should be possible to produce them in
sufficient bulk and affordably for distribution in the
developing world where these agents are needed most.
Interestingly, while having equipotent antiviral activity in
vitro and in vivo, these two new molecules have distinctly
different mechanisms of action. Similar to PSC-RANTES,
6P4-RANTES is a CCR5 agonist that activates cell signaling
cascades and receptor internalization after binding. By
contrast, 5P12-RANTES binding fails to properly activate
the receptor (no observed changes in intracellular calcium
levels) and does not promote CCR5 internalization. It
remains to be seen whether simple receptor occupancy
without cellular activation will prove a better topical pre-
vention strategy than durable coreceptor internalization
with induced cellular activation. Perhaps the ideal strategy
will be one that promotes durable receptor internalization
without signal transduction, and development of such a
molecule may be achievable. Other G-protein-coupled
receptors can be internalized by internalized by certain
ligands without demonstrable agonist activation [92-95].
Already, one chemokine analog, 5P14-RANTES [96], has
been identified that is as potent as PSC-RANTES, does not
stimulate Ca2+ flux, but induces the sequestration of
CCR5 with approximately half the efficiency of PSC-
RANTES and 6P4-RANTES.
Combination strategies
Combination antiretroviral therapies have proven enor-
mously successful in the treatment of established HIV
infection. In fact, single agent strategies have invariably
failed, in large part due to the predictable emergence of
viruses that contain mutations conferring resistance to the
antiviral drug. Though the principles are not exactly the
same, there are solid rationales to the development of
combination strategies for the topical prevention of HIV
mucosal transmission. First, while emergence of resist-
ance is unlikely to occur upon HIV exposure during sex
with an infected partner, the increasing transmission of
drug resistant viruses among newly infected persons
[97,98] may render some topical prevention strategies less
effective (see below). Thus combinations of agents that
disrupt different elements of the HIV life cycle may also
provide a broader safety net of protection. Second, addi-
tive or synergistic activities might enhance the level of pro-
tection against the establishment of infection. Using SHIV
162P3 in a macaque vaginal challenge model, Veazey et al.
have shown that combinations of agents that block viral
entry provide better levels of protection than any single
agent used alone [58]. While CMPD 167, C52L, BMS
378806 failed to completely protect challenged animals
alone, combinations of two and all three of these agents
proved fully protective. Unfortunately, before a single
agent is proven to be safe and effective, there are practical
(e.g. formulation) and registrational hurdles to the devel-
opment of combinations of active agents as topical pre-
vention strategies. We do not believe these hurdles to be
insurmountable. Formulations compatible with multiple
active agents can be developed and agencies charged with
oversight of drug development can work closely with
investigators to design and accelerate the pace of studies
designed to test the safety and activity of plausible combi-
nation prevention strategies.
Additional comments
As has been stated by nearly every researcher in the field,
a successful "microbicide" or topical prevention strategy
must be safe, effective and affordable. There are currently
a good number of promising candidates under develop-
ment, including inhibitors of entry as well as inhibitors of
other elements of the viral life cycle[12]. Unfortunately,
the field (and public perceptions of the field) has been
considerably damaged by a number of widely publicized
dramatic failures of large test of efficacy studies, some of
which have actually increased the risk of HIV transmission
(reviewed in [99]). While the urgent need to halt the
spread of the epidemic is real, the field needs to be more
selective about which agents to bring forward into large
efficacy studies. Candidates for topical prevention strate-
gies must have a plausible chance for succeeding. Thus,
they must be effective in preclinical studies that include
protection of non-human primates from infection with an
R5 tropic virus. The agents must be safe. Thus, they must
be well tolerated after multiple applications in women
who are at low risk for HIV infection and must not induce
the inflammation that has been linked to an increased riskRetrovirology 2008, 5:116 http://www.retrovirology.com/content/5/1/116
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for HIV transmission. Ideally, they should not perturb the
normal vaginal microbiota, nor increase risks for acquisi-
tion of other sexually transmissible infections. Finally,
these drugs should have durable activity. Analyses from a
failed prevention trial suggest that agents requiring appli-
cation just prior to coitus are not likely to be used often
enough to provide sufficient protection [100]. Thus, only
strategies that provide substantial protection from infec-
tion for at least a full day or even longer are likely to prove
effective in clinical settings. It remains to be seen whether
durable protection can be provided by formulation in
slow release gels or films or by application using vaginal
rings that have been used for slow release of contracep-
tives[101,102].
It may be problematic to apply a strategy for topical pre-
vention in a community that is using the same strategy for
treatment. First, the predictable emergence of resistance
during therapy may render that strategy less effective
when applied to prevent the initial acquisition of infec-
tion. Second, topical application of an antiviral drug by
persons who are unknowingly infected may provide suffi-
cient selection pressure systemically or even at mucosal
and peri-mucosal sites of HIV replication to induce emer-
gence of resistance, rendering subsequent treatment less
effective. How much of an issue these concerns will be
remains to be seen, but they provide some rationale for
the need to develop different strategies for treatment and
for prevention. Lastly, a major rate limiting step to the
implementation of a topical HIV prevention strategy is the
cost of development. The cost can be measured both in
real dollars and in expertise. Most scientists engaged in
this new area of prevention research are not experts in
drug development. Those with the managerial and scien-
tific expertise to bring a new drug to the clinic are found
in the pharmaceutical industry, which, for the most part,
has steered clear of topical HIV prevention strategies for
market reasons. Getting these companies engaged in a
substantive way might help accelerate the process.
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